FDA Determines Regulatory Review Period for BULKAMID Urethral Bulking System Patent Extension

Summary

The US Food and Drug Administration (FDA) has published a notice determining the regulatory review period for the BULKAMID Urethral Bulking System, a medical device, in response to patent extension applications submitted to the US Patent and Trademark Office (USPTO).